Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a research study in 2 parts assessing the following parameters of the combination of
the study drug called bosutinib, and a drug called capecitabine: the safety, how well the
subject's body handles the study drug, and preliminary anti-tumor activity as treatment for
different types of cancers in part 1, and breast cancer only in part 2.
In part 1, subjects will receive bosutinib and capecitabine daily at different dose levels of
each drug in order to determine the highest tolerated dose of the combination study
treatment. In part 2, subjects will receive bosutinib and capecitabine at this highest
tolerated dose to see how well the study treatment works to treat breast cancer. In addition,
genetic research testing (research analyses involving genes and gene products) will be
performed on biological samples from subjects.